Nuclear cardiology: A European perspective by Delaloye, Angelika
EDITORIAL POINT OF VIEW 
Nuclear cardiology: A European perspective 
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From the European point of view, the term "nuclear 
cardiology" is inappropriate because there is no specific 
certification i nuclear cardiology; however, this term has 
entered common medical language and therefore will be 
used here as a synonym of nuclear medicine in cardiolo- 
gy and cardiovascular nuclear medicine. 
It is difficult to give an overall impressio n on the 
European situation because quipment, regulations and, 
last but not least, medical practice patterns differ from 
one country to the other even within the European Union. 
On the European level, nuclear medicine has been recog- 
nized as a full medical specialty since 1989. In many 
European countries it is not possible to practice medicine 
in more than one specialty even if fully trained in more 
than one. In some countries these regulations are chang- 
ing, and physicians are or will be allowed to have more 
than one specialist title provided they fulfill the require- 
ments of continuing education in all specialties. 
According to a survey published in a 1996 position paper 
by the Nuclear Medicine Section of the Union of 
European Medical Specialists (UEMS), 1 nuclear medi- 
cine studies in cardiology are mostly performed by certi- 
fied nuclear medicine specialists. For legal reasons, only 
these specialists are allowed to administer radioactive 
tracers to patients. In the Scandinavian countries, clinical 
physiology deals with all kinds of functional studies, 
including those performed with radioactive tracers. In the 
other countries, a few nonnuclear medicine physicians 
(cardiologists, radiologists) perform such studies. In 
many centers, cardiologists perform or at least are pres- 
ent during stress tests, but only in a small number of 
countries is their presence mandatory. 
Training in nuclear medicine varies from country to 
country as well. A 1996 syllabus prepared by The 
European Board of Nuclear Medicine (EBNM) listed the 
minimal requirements for training as at least 3 years in 
nuclear medicine and 1 or 2 years in one or more other 
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specialties. This training period is to include clinical 
activity with bedside training and performance of a min- 
imum of 500 nuclear cardiology studies. The revised 
form of this syllabus has been published in the European 
Journal of Nuclear Medicine. 2All of these requirements, 
of course, must be considered only as directives that can, 
but need not, be accepted as the foundation of laws and 
rules that are set up at the national level. 
Since 1993 the proportion of presentations in the 
cardiovascular domain during the European Annual 
Meetings of the European Association of Nuclear 
Medicine (EANM) tends to diminish slightly. There are 
probably several reasons for this apparent decrease 
(Table 1), which should not be interpreted as a decrease 
of scientific activity in this field'. Other topics that have 
gained interest (in particular oncology) fill time slots 
previously available for cardiology papers. The absolute 
number of presented abstracts remained rather stable 
except for the number presented at the last meeting, 
which clashed with the annual meeting of the European 
Society of Cardiology (ESC). Considering that 90 
nuclear medicine papers were selected for presentation 
there and 110 at the EANM meeting, the scientific inter- 
est in this field seems well preserved. Not only quantity 
but also quality seems to be at good levels: the rejection 
rate of nuclear medicine and radiology abstracts at the 
ESC meeting was 26% compared with an overall rejec- 
tion rate of 48%. 
In addition to these two large European meetings, 
the International Conference of Nuclear Cardiology 
(ICNC) in early 1997 also drained an important number 
of presentations that otherwise would have been submit- 
ted to the annual meeting. 
As for bone scans, which are widely performed but 
are the subject of only a very limited number of abstracts 
submitted to the EANM Annual Congress, myocardial 
perfusion studies are today considered routine and are no 
longer the subject of widespread methodologic debate 
even if the final standard of performing such studies till 
needs to be defined. Due to the importance of myocardial 
perfusion imaging, nuclear cardiology occupies the sec- 
ond or third position of the number of nuclear medicine 
studies in most countries despite the contraction of the 
volume of radionuclide ventriculography, which tends to 
be replaced by echocardiography. 3 
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The scientific interest in myocardial perfusion and 
viability imaging has shifted from methodology toques- 
tions such as standardization, quality control, clinical 
impact, decision-making, cost-efficacy, and cost-benefit. 
A recent European cost-benefit study has shown that 
diagnostic management strategies that include myocar- 
dial perfusion imaging in the evaluation of patients with 
possible coronary artery disease generate significantly 
fewer costs than strategies that do not include the nuclear 
medicine test. This difference in cost is not only observed 
at diagnosis but persists after 2 years of follow-up. 4
In addition to lower costs, strategies including 
myocardial perfusion imaging have higher diagnostic 
power at diagnosis and a lower negative coronary angiog- 
raphy rate. These results, which were collected in four 
western European countries, are an important signal to 
health authorities, hospital managers, and insurance com- 
panies. The discussion on the cost-effectiveness of 
assessing hibernating myocardium is ongoing. 5 
Medical practice and availability of medical 
resources differ within the European Union already, but 
the differences are even more important when we also 
take into consideration the situation i  eastern and central 
Europe. Many of our colleagues in those countries who 
have had access to modern technology only recently and 
in a very limited fashion have made a tremendous effort 
to make these newer techniques available to their col- 
leagues and patients and to promote training of medical 
and technical staff. 
The penetration of myocardial perfusion imaging 
still shows great variations from one country to the other. 
The following comments are based on a survey by 
Iskandrian and Giubbini 6that compared nuclear cardiol- 
ogy in the United States and Europe. They showed that 
the number of myocardial perfusion studies per million 
inhabitants varied greatly even within the European 
Union, with the high being 8400 in Belgium and the low 
264 in Ireland. As expected, the number of myocardial 
perfusion studies is still much lower (173/million inhab- 
itants) in eastern and central European countries. At first 
glance, the density of gamma cameras appears to play a 
role in this difference because Belgium has the highest 
density in Europe (24/million inhabitants), but Ireland is 
not at the other extreme for the camera density. There are 
more cameras in Ireland than in Portugal after normal- 
ization for the population, but the number of myocardial 
perfusion studies per gamma camera is only 58 in Ireland 
and 285 in Portugal, which is well beyond the European 
annual average of 183. 
Table 2 compares the distribution in percentage of 
scientific presentations in the field of cardiology at the 
1997 EANM Congress in Glasgow 7 and of the myocar- 
dial perfusion studies performed in Europe. 6 In most 
countries there is a balance between the scientific and 
Table 1. Presentations in the field of cardiology in 
percentage of all (oral and poster) presentations 
during the annual meetings of the European 
Association of Nuclear Medicine since 1990 
Year Presentations (%) 
1990 14.0 
1991 14.4 
1992 16.2 
1993 20.7 
1994 18.0 
1995 16.4 
1996 15.8 
1997 13.0 
clinical activity in cardiology, with myocardial perfusion 
imaging representing by far the most important part. It is 
worth noting that in Greece, Turkey, and eastern and cen- 
tral European countries, scientific participation exceeds 
the clinical activity by a factor of 2, 4, and 3, respective- 
ly. The situation in Belgium is special. In this country we 
find not only the highest gamma-camera density, but also 
the greatest imbalance in favor of the clinical activity. 
This finding does not mean that the scientific activity in 
this country is poor; in fact, the percentage of presenta- 
tions is 1.7 times higher than the percentage of the 
Belgian population in Europe, which indicates a scien- 
tific productivity with respect o the number of inhabi- 
tants comparable tothat of Germany. 
There are probably several other reasons for this 
imbalance which might have socioeconomic and cul- 
tural roots. The greater availability of camera time, and 
thus the absence of waiting lists, is certainly not a 
major argument because the number of studies per- 
formed per camera is much higher (350) than in all of 
the other European countries except France (395). I 
dare to speculate that the popularity of nuclear cardi- 
ology in Belgium results from its development by a 
certain number of nuclear physicians trained in cardi- 
ology whose academic and clinical activity was either 
preferentially or exclusively devoted to nuclear medi- 
cine in cardiology, which favored the clinical impact of 
the technique. 
In my opinion, this shows the importance of cooper- 
ation between the two specialties to promote nuclear 
medicine in cardiology. First, we need to speak a com- 
mon language. 8 The nuclear physician eeds to under- 
stand what information the cardiologist needs to manage 
cases efficiently, and this information must be given in 
clinical terms. According to the EBNM syllabus inter- 
preted for the field of cardiovascular nuclear medicine, 
trainees in nuclear medicine should follow a program 
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Table 2. Distribution (%) for the various European countries of population, myocardial perfusion studies (MPS) 
and scientific presentations in the field of cardiology during the 1997 EANM Congress 
Country Population MPS Presentations 
Austria 1.5 2.9 1.1 
Belgium 1.9 11.7 3.3 
Denmark 1.9 0.5 0 
France 11.0 14.3 10.9 
Finland 1.0 14.3 10.9 
Germany 15.6 30.0 27.2 
Greece 0.7 2.7 5.4 
Ireland 10.8 0.1 0 
Luxembourg 0.1 NA NA 
Portugal 1.9 0.8 0 
Spain 7.5 .7 5.4 
Sweden 1.6 2.5 1. l 
The Netherlands 2.9 5.2 6.5 
United Kingdom 11.0 7.2 6.5 
Norway 0.8 0.5 0 
Switzerland 1.3 1.9 2.2 
Turkey 9.7 1.6 6.5 
Eastern/Central Europe 17.9 2.3 7.6 
that includes, if not bedside training in a cardiology 
ward, at least regular participation in clinical confer- 
ences with cardiologists and cardiovascular surgeons in 
addition to sufficient raining in theory and practice of 
nuclear medicine techniques in cardiology. To give com- 
petent advice about he potential contribution of nuclear 
medicine techniques, trainees must learn to appreciate 
the value of the available investigations in cardiology 
and not just those of nuclear medicine. 
In my opinion, however, aside from the questions 
of laws and regulations, it does not seem reasonable in
the present European situation to create a specialty of 
nuclear cardiology. In the European community, an 
average of 183 myocardial perfusion studies are per- 
formed per gamma camera, which amounts to less than 
1 study per working day. This relatively small volume 
does not justify the exclusive use of gamma cameras 
for cardiology. We need to consider that many, if not a 
majority of, nuclear medicine facilities work with a 
single gamma camera. 9 
The absence of a sufficient volume of cardiac stud- 
ies to ensure the profitability of a dedicated camera is 
not the only obstacle to setting up special facilities for 
nuclear cardiology. Overall, high-quality nuclear cardi- 
ology not only requires knowledge in cardiology, but it 
also includes thorough understanding of tracer kinetics, 
physics of radionuclide imaging including tomography, 
attenuation and scatter correction, reconstruction algo- 
rithms, as well as preparation and administration of 
radioactive tracers, quality control of gamma cameras 
and radiopharmaceuticals, dosimetry, and radioprotec- 
tion. These are the foundations of nuclear medicine 
applied to any of the clinical sciences, be it endocrinol- 
ogy, gastroenterology, neurology, nephrourology, oncol- 
ogy, pediatrics, or rheumatology, not just cardiology. In 
a period of cost-awareness, it is difficult to conceive that 
costly gamma-camera computer systems are dedicated 
to one single organ, but neither is it acceptable to use 
such systems without ensuring the highest clinical 
impact of the studies. 
To find a common platform while respecting the 
European socioeconomic and cultural diversity, we have 
chosen to favor cooperation between cardiologists and 
nuclear medicine specialists rather than the development 
of a new medical specialty and, by this pragmatic 
approach, to close at least momentarily, the debate on 
nuclear cardiology.10,11 We have recently formalized the 
unofficial partnership that already existed between cer- 
tain members of the Working Group on Nuclear 
Cardiology and Magnetic Resonance of the ESC and the 
Cardiovascular Committee of the EANM. This informal 
collaboration was already very successful in participating 
in the ICNCs and in setting up protocols for cardiac 
radionuclide studies, 12 but it is time to formalize this 
relation between the two European societies. The prima- 
ry goals of this formal partnership are the "clinical pro- 
motion of nuclear cardiology and related areas, the train- 
ing and continuing education of medical and technical 
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specialists, and the establishment and maintenance of 
clinical standards in the field." It is not intended to create 
a special society of nuclear cardiology. Both groups rec- 
ognize the independent specialties of cardiology and 
nuclear medicine and intend to improve collaboration to
the advantage of the cardiac patient. We think that this is 
an important step forward to promote nuclear medicine 
in the field of cardiology in a structured way instead of 
relying on the good will of people who are, by chance, 
members of both the EANM and ESC. 
This joint group will also be the European partner of 
the American Society of Nuclear Cardiology in the orga- 
nization and support of the next ICNC and possibly in 
other actions to promote the use of radioactive tracers in 
research and clinical applications i  cardiology. 
By joining our knowledge, our understanding, our 
competence, and our ideas we will be stronger than if 
each specialty works alone. Through the ESC and 
EANM working group and committee dealing with 
nuclear medicine and cardiology, we have created the 
forum where such an exchange and collaboration can 
take place to promote nuclear medicine and cardiology 
by interactive research and training, setting of standards 
and mechanisms of controlling them, and favoring the 
development of both specialties for the sake of cardiac 
patients in Europe. 
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